Table 3 Characteristics of patients eligible for RIOP and TARGIT E trials of the G3S (R1E and T1E) and cohort 2 (R2E and T2E)
COHORT G3S | COHORT 2 | ||||
|---|---|---|---|---|---|
R1E | T1E | R2E | T2E | ||
n | 499/1411 (36.8%) | 859/1411 (60.9%) | 114/592 (19.3%) | 268/592 (45.3%) | |
Age | |||||
Median | 73 | 73 | 74 | 74 | |
Range | 70–100 | 70–101 | 70–91 | 70–94 | |
Tumor size mm | |||||
Median (CI95 %) | 10 (10.7–11.4) | 11 (11.7–12.6) | 12 (11.4–13.1) | 15 (14.1–15.8) | |
Range | 1–20 | 0,2–35 | 3–20 | 3–34 | |
Histology | |||||
Ductal | 423 (84.8%) | 748 (87.5%) | 114 (100%) | 268 (100%) | |
Lobular | 0 | 0 | 0 | 0 | |
Mixed | 0 | 0 | 0 | 0 | |
Other | 76 (15.2%) | 107 (12.5%) | 0 | 0 | |
Grade | |||||
1 | 268 (53.7%) | 358 (42.3%) | 1–2 | 114 (100%) | 229 (88.1%) |
2 | 231 (46.3%) | 367 (43.3%) | 3 | 0 | 31 (11.9%) |
3 | 0 | 109 (12.9%) | |||
Unknown | 0 | 0 | |||
pN | |||||
pN0 | 499 (100%) | 858 (100%) | pN0 | 114 (100%) | 243 (90.7%) |
i+ | 0 | 0 | ≤3 | 0 | 0 |
mic | 0 | 0 | >3 | 0 | 0 |
macro | 0 | 0 | unknown | 0 | 25 (9.3%) |
HR | |||||
+ | 499 (100%) | 745 (89,4%) | 114 (100%) | 175 (65,5%) | |
- | 0 | 88 (10,6%) | 0 | 92 (34,5%) | |
Her2 amplification | |||||
Yes | 13 (3.7%) | 31 (5.6%) | 2 (7.4%) | 8 (17.8%) | |
No | 337 (96.3%) | 525 (94.4%) | 25 (92.6%) | 37 (82.2%) | |
Lymphovascular invasion | |||||
Yes | 0 | 0 | 0 | 0 | |
No | 499 (100%) | 673 (100%) | 114 (100%) | 243 (100%) | |
Margins | |||||
Positive | 0 | 0 | 0 | 0 | |
Negative | 499 (100%) | 859 (100%) | 114 (100%) | 268 (100%) | |
Multifocality | |||||
Yes | 0 | 0 | 0 | 0 | |
No | 499 (100%) | 859 (100%) | 114 (100%) | 268 (100%) | |
Chemotherapy | |||||
Yes | 11 (2.4%) | 54 (6.9%) | 11 (9.6%) | 39 (14.6%) | |
No | 440 (97.6%) | 724 (93.1%) | 103 (90.4%) | 229 (85.4%) | |
Hormonotherapy | |||||
Yes | 428 (86.7%) | 670 (78%) | 114 (100%) | 175 (65.5%) | |
No | 69 (13.9%) | 189 (22%) | 0 | 92 (34.5%) | |